Amylin, Eli Lilly, Alkermes Submit Reply to FDA on Bydureon

Three partners on diabetes drug Bydureon — Amylin Pharmaceuticals, Eli Lilly and Alkermes — submitted a response to the U.S. Food and Drug Administration that includes additional data indicating the drug didn’t slow heart rates.
The Wall Street Journal